Table 1 Overview of drug collection
From: Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma
Drug class | Approved | Investigational (Phase I-III) | Preclinical | Total |
|---|---|---|---|---|
Conventional chemotherapy | 58 | 5 | 3 | 66 |
Kinase inhibitor | 32 | 172 | 26 | 230 |
Rapalog | 4 | 1 | 0 | 5 |
Immunomodulatory | 10 | 3 | 0 | 13 |
Differentiating/epigenetic modifier | 10 | 21 | 20 | 51 |
Hormone therapy | 18 | 3 | 1 | 22 |
Apoptotic modulator | 0 | 12 | 3 | 15 |
Metabolic modifier | 8 | 5 | 4 | 17 |
Kinesin inhibitor | 0 | 3 | 0 | 3 |
NSAID | 2 | 0 | 0 | 2 |
Heat shock protein inhibitor | 0 | 6 | 2 | 8 |
Proteasome inhibitor | 2 | 1 | 1 | 4 |
Hedgehog inhibitor | 1 | 1 | 0 | 2 |
Other | 7 | 8 | 8 | 23 |
Total number (% of total) | 152 (33%) | 241 (52%) | 68 (15%) | 461 |